{
    "clinical_study": {
        "@rank": "124560", 
        "arm_group": [
            {
                "arm_group_label": "nalbuphine HCl ER 60mg", 
                "arm_group_type": "Experimental", 
                "description": "nalbuphine HCl ER 60mg BID"
            }, 
            {
                "arm_group_label": "nalbuphine HCl ER 90mg", 
                "arm_group_type": "Experimental", 
                "description": "nalbuphine HCl ER 90mg BID"
            }, 
            {
                "arm_group_label": "nalbuphine HCl ER 120mg", 
                "arm_group_type": "Experimental", 
                "description": "nalbuphine HCl ER 120mg BID"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER\n      tablets during a treatment period of up to 24 weeks."
        }, 
        "brief_title": "Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Uremic Pruritus", 
            "Pruritus"
        ], 
        "condition_browse": {
            "mesh_term": "Pruritus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject completed participation in the TR02 study\n\n          -  Subject is currently receiving in-center hemodialysis at the time of consent\n\n        Exclusion Criteria:\n\n          -  Subject receiving or anticipated to be receiving nocturnal dialysis or home\n             hemodialysis treatment during the study\n\n          -  Subject received opiates on a daily basis during the 1 week  prior to screening\n\n          -  Other than the TR02 Study Drug, Subject received any investigational drug within 4\n             weeks prior to Screening\n\n          -  Subject is a pregnant or lactating female"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143973", 
            "org_study_id": "TR02ext", 
            "secondary_id": "2013-005625-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "nalbuphine HCl ER 60mg", 
                "description": "nalbuphine HCl ER 60mg BID for up to 24 weeks", 
                "intervention_name": "nalbuphine HCl ER 60mg BID", 
                "intervention_type": "Drug", 
                "other_name": "nalbuphine"
            }, 
            {
                "arm_group_label": "nalbuphine HCl ER 90mg", 
                "description": "nalbuphine HCl ER 90mg BID for up to 24 weeks", 
                "intervention_name": "nalbuphine HCl ER 90mg BID", 
                "intervention_type": "Drug", 
                "other_name": "nalbuphine"
            }, 
            {
                "arm_group_label": "nalbuphine HCl ER 120mg", 
                "description": "nalbuphine HCl ER 120mg BID for up to 24 weeks", 
                "intervention_name": "nalbuphine HCl ER 120mg BID", 
                "intervention_type": "Drug", 
                "other_name": "nalbuphine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nalbuphine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Uremic", 
            "Pruritus", 
            "Itch", 
            "Chronic Itch", 
            "Nalbuphine"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Springfield", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01107"
                }, 
                "name": "Baystate Health"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus", 
        "overall_contact": {
            "email": "roberta.duncan@trevitherapeutics.com", 
            "last_name": "Roberta Duncan", 
            "phone": "203-304-2499"
        }, 
        "overall_contact_backup": {
            "last_name": "Thomas Sciascia, MD", 
            "phone": "203-304-2499"
        }, 
        "overall_official": {
            "affiliation": "Trevi Therapeutics", 
            "last_name": "Thomas Sciascia, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "A description of the overall incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143973"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "A description of the incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs) during Treatment by achieved dose", 
            "safety_issue": "Yes", 
            "time_frame": "Week 3, Week 24"
        }, 
        "source": "Trevi Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Trevi Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}